JP2017537117A - 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療 - Google Patents
小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療 Download PDFInfo
- Publication number
- JP2017537117A JP2017537117A JP2017530277A JP2017530277A JP2017537117A JP 2017537117 A JP2017537117 A JP 2017537117A JP 2017530277 A JP2017530277 A JP 2017530277A JP 2017530277 A JP2017530277 A JP 2017530277A JP 2017537117 A JP2017537117 A JP 2017537117A
- Authority
- JP
- Japan
- Prior art keywords
- wamd
- treatment
- week
- cnv
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
Description
ベバシズマブ(Avastin(登録商標)) WO 9845331
ラニビズマブ(Lucentis(登録商標)) WO 9845331
ペガプタニブ(Macugen(登録商標)) WO 9818480
KH−902/conbercept(Langmu(登録商標)) WO 2007112675
1)「sCNV wAMD」
2)「小さい活動性CNVを有するwAMD」
3)「活動性CNVが減少したwAMD」
4)「CNVがより少ないwAMD」
5)「非CNV関連のwAMD」
6)「wAMDタイプ1」
7)「wAMDタイプ2」
8)「wAMDタイプX」(Xは任意の数字、文字または両方の組み合わせ)。
a.「湿潤AMD」
b.「血管新生性AMD」
c.「nAMD」
d.「滲出型AMD」
e.「eAMD」
1)「pCNV wAMD」
2)「活動性CNVを主体とするwAMD」
3)「活動性CNVを有するwAMD」
4)「大きな活動性CNVを有するwAMD」
5)「CNV関連wAMD」
6)「wAMDタイプ1」
7)「wAMDタイプ2」
8)「wAMDタイプX」(Xは任意の数字、文字または両方の組み合わせ)。
a.「湿潤AMD」
b.「血管新生性AMD」
c.「nAMD」
d.「滲出型AMD」
e.「eAMD」
1)「sCNV wAMD」は、全病変サイズの50%未満を占める活動性CNV病変を特徴とする
2)「pCNV wAMD」は、全病変サイズの少なくとも50%を占める活動性CNV病変を特徴とする。
1)wAMDの治療と同様の硝子体内抗VEGF単独療法であるが、抗VEGF療法は、眼内の遊離VEGFを減弱させることを目的とした認可された治療および認可されていない治療すべてを指す。これには、特にアフリベルセプト、ラニビズマブ、ベバシズマブ、KH−902およびペガプタニブが含まれるが、これらの化合物に限定されない。抗VEGF治療は、以下の治療スケジュールにしたがって施すことができる:
a.毎月の硝子体内注射3回または4週間ごとの硝子体内注射3回、続いて隔月または4週間ごとに投与し、後の治療段階は、さらに治療間隔を延ばす選択肢あり、またはなしで投与する。
b.視力および/または網膜形態(例えば、OCT、フルオレセイン血管造影、インドシアニン血管造影、眼底検査などによって評価される。)まで治療が安定化し、続いて治療を中止する。視力および/または網膜形態の悪化時に治療を再開。
c.必要に応じて(pro−re−nata−「PRN」)任意のレジメン
d.任意の治療および延長レジメン
e.wAMDの治療に使用されている、または使用された他の任意の治療レジメン
a.1)に記載の抗VEGF治療
b.Visudyne(登録商標)(V(登録商標)−PDT)を用いる光線力学療法の単回または反復適用
c.徐放性製剤またはデポー製剤(例えば、Ozurdex(登録商標)、トリアムシノロン、デキサメタゾン、Iluvien(登録商標)など)を含むステロイドの単回または反復適用(すべての利用可能な局所または全身投与経路)
d.放射線療法
e.閾値以下の治療を含む熱レーザー療法
f.外科療法
g.薬理学的な硝子体液化(pharmacological vitreolysis)(例えば、Jetria(登録商標)あるいは他の認可された薬剤または認可されていない薬剤による)
h.全身的または局所的に適用されるチロシンキナーゼの阻害剤
i.全身的または局所的に適用されるVEGF受容体の阻害剤
加齢性血管新生または湿潤加齢性黄斑変性症を有する合計304人の中国人被験者を無作為化二重盲検臨床試験に登録して、V(登録商標)−PDTと比較した硝子体内(IVT)投与したアフリベルセプトの有効性を、BCVA(最高矯正視力)のベースラインからの平均変化で第28週まで評価した。試験眼のBCVAを、加齢性眼疾患調査(Age Related Eye Disease Study)(AREDS)に適合させたETDRS(早期治療糖尿病性網膜症調査(Early Treatment Diabetic Retinopathy Study))のために開発された標準的な手順にしたがって評価した。重要な組み入れ基準は以下の通りであった。
署名し、日付を入れた書面によるICF。
50歳以上の男性と女性。
試験眼においてフルオレセイン蛍光眼底造影(FA)によって明らかになる、中心窩に影響を及ぼす傍中心窩病変を含む、AMDに続発するクラシック主体型活動性中心窩下脈絡膜新生血管(CNV)病変。
CNVの領域は、全病変の少なくとも50%を占有しなければならなかった。
ETDRSの試験眼の最高矯正視力(BCVA)は73〜25文字(試験眼のスネレン等価視力は20/40〜20/320)。
全病変サイズは、FAによって評価される12の乳頭領域(30.5mm2、血液、瘢痕および新生血管を含む。)より大きい。
網膜下出血は全病変領域の50%以上であるか、または血液が中心窩の下にある場合、1つまたは複数の乳頭領域のサイズである。(血液が中心窩の下にある場合、中心窩は目に見えるCNVによって270度囲まれていなければならない)
wAMD以外の起源を持つCNVの存在。糖尿病性網膜症、糖尿病性黄斑浮腫またはwAMD以外の何らかの網膜血管疾患の病歴または臨床的証拠。ポリープ状脈絡膜血管症(PCV)を有する被験者を除外するために、特に注意が払われるべきである。
実質的に不可逆的な視力喪失を示す中心窩を含む瘢痕、線維症または萎縮症の存在。
網膜色素上皮断裂または黄斑に関与する裂け目の存在。
Claims (12)
- 患者の湿潤加齢黄斑変性症(wAMD)を治療するための方法であって、CNV病変の活動性サイズが全病変サイズの50%未満である場合にまず確立され、次いで、前記CNV病変の前記活動性サイズが前記全病変サイズの50%未満である場合に、通常のwAMD治療スキームにしたがって前記患者が治療される方法。
- 前記CNV病変の前記活動性サイズが前記全病変サイズの50%未満である場合に、抗VEGF治療により前記患者が治療される、請求項1に記載の方法。
- 最初の抗VEGF療法が、それぞれ4週間、8週間、12週間以上ごとの抗VEGF療法のための医薬組成物の単回注射または2回、3回、4回、5回、6回以上の注射からなる、請求項2に記載の方法。
- 前記抗VEGF療法の少なくとも3回の投与が4週間ごとに投与される、請求項2に記載の方法。
- 治療反応の評価が、先行する抗VEGF療法の4週間、8週間、12週間以上後に実施される、請求項2に記載の方法。
- 前記抗VEGF治療が、アフリベルセプト、ラニビズマブ、ベバシズマブ、KH−902またはペガプタニブから選択される化合物の投与を含む、請求項2、3、4または5に記載の方法。
- 前記CNV病変の前記活動性サイズが前記全病変サイズの50%未満である場合に、光増感剤を用いてPDTにより前記患者が治療される、請求項1に記載の方法。
- 前記治療が、光増感剤としてのベルテポルフィンの投与を含む、請求項7に記載の方法。
- 抗VEGF剤を含む、sCNV wAMDの治療における使用のための医薬組成物。
- アフリベルセプト、ラニビズマブ、ベバシズマブ、KH−902またはペガプタニブを含む、請求項9に記載の医薬組成物。
- 光増感剤を含む、sCNV wAMDの治療のための医薬組成物。
- 光増感剤としてベルテポルフィンを含む、請求項11に記載の医薬組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2014/093548 WO2016090590A1 (en) | 2014-12-11 | 2014-12-11 | Treatment of age related macular degeneration with a small active choroidalneovascularizationlesion |
CNPCT/CN2014/093548 | 2014-12-11 | ||
CNPCT/CN2015/089251 | 2015-09-09 | ||
CN2015089251 | 2015-09-09 | ||
PCT/US2015/065022 WO2016094673A1 (en) | 2014-12-11 | 2015-12-10 | Treatment of age related macular degeneration with a small active choroidal neovascularization lesion |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020173951A Division JP2021004262A (ja) | 2014-12-11 | 2020-10-15 | 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017537117A true JP2017537117A (ja) | 2017-12-14 |
JP7320919B2 JP7320919B2 (ja) | 2023-08-04 |
Family
ID=55069121
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017530277A Active JP7320919B2 (ja) | 2014-12-11 | 2015-12-10 | 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療 |
JP2020173951A Pending JP2021004262A (ja) | 2014-12-11 | 2020-10-15 | 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療 |
JP2022152791A Pending JP2022183183A (ja) | 2014-12-11 | 2022-09-26 | 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020173951A Pending JP2021004262A (ja) | 2014-12-11 | 2020-10-15 | 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療 |
JP2022152791A Pending JP2022183183A (ja) | 2014-12-11 | 2022-09-26 | 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療 |
Country Status (16)
Country | Link |
---|---|
US (2) | US20170326106A1 (ja) |
EP (2) | EP3230316B1 (ja) |
JP (3) | JP7320919B2 (ja) |
CN (3) | CN114306575A (ja) |
AU (3) | AU2015360496B2 (ja) |
CA (1) | CA2970315C (ja) |
DK (1) | DK3230316T3 (ja) |
ES (1) | ES2907148T3 (ja) |
HR (1) | HRP20220066T1 (ja) |
HU (1) | HUE057653T2 (ja) |
LT (1) | LT3230316T (ja) |
PL (1) | PL3230316T3 (ja) |
PT (1) | PT3230316T (ja) |
RS (1) | RS62827B1 (ja) |
SI (1) | SI3230316T1 (ja) |
WO (1) | WO2016094673A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2004697A2 (en) | 2006-04-07 | 2008-12-24 | The Procter & Gamble Company | Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
US20170326106A1 (en) | 2014-12-11 | 2017-11-16 | Bayer Healthcare Llc | Treatment of age related macular degeneration with a small active choroidal neovascularization lesion |
WO2016100851A1 (en) * | 2014-12-18 | 2016-06-23 | Lankenau Institute For Medical Research | Methods and compositions for the treatment of retinopathy and other ocular diseases |
BR112018013407A2 (pt) | 2015-12-30 | 2018-12-18 | Kodiak Sciences Inc | anticorpos e conjugados dos mesmos |
CN112739323A (zh) | 2018-05-10 | 2021-04-30 | 瑞泽恩制药公司 | 含有高浓度vegf受体融合蛋白的制剂 |
WO2020068653A1 (en) | 2018-09-24 | 2020-04-02 | Aerpio Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF |
EP4041312A4 (en) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | METHOD FOR TREATING AN EYE DISORDER |
US11944663B2 (en) * | 2020-06-18 | 2024-04-02 | Chengdu Kanghong Biotechnologies Co. Ltd. | Method for treating angiogenic eye disorders using VEGF antagonists |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002062386A2 (en) * | 2001-02-06 | 2002-08-15 | Qlt Inc. | Photodynamic therapy of occult choroidal neovascularization linked to age-related macular degeneration |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2259188T3 (es) | 1996-10-25 | 2006-09-16 | Gilead Sciences, Inc. | Complejos de ligando de acido nucleico de factor de crecimiento endotelial vascular (vegf). |
JP3957765B2 (ja) | 1997-04-07 | 2007-08-15 | ジェネンテク・インコーポレイテッド | 抗vegf抗体 |
CA2376379C (en) | 1999-06-08 | 2007-08-07 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
CN100502945C (zh) | 2006-03-31 | 2009-06-24 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在治疗眼睛疾病中的应用 |
KR20180023015A (ko) * | 2011-01-13 | 2018-03-06 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
US20170326106A1 (en) | 2014-12-11 | 2017-11-16 | Bayer Healthcare Llc | Treatment of age related macular degeneration with a small active choroidal neovascularization lesion |
-
2015
- 2015-12-10 US US15/534,030 patent/US20170326106A1/en not_active Abandoned
- 2015-12-10 WO PCT/US2015/065022 patent/WO2016094673A1/en active Application Filing
- 2015-12-10 AU AU2015360496A patent/AU2015360496B2/en active Active
- 2015-12-10 HU HUE15819965A patent/HUE057653T2/hu unknown
- 2015-12-10 CN CN202210019267.XA patent/CN114306575A/zh active Pending
- 2015-12-10 PL PL15819965T patent/PL3230316T3/pl unknown
- 2015-12-10 LT LTEPPCT/US2015/065022T patent/LT3230316T/lt unknown
- 2015-12-10 ES ES15819965T patent/ES2907148T3/es active Active
- 2015-12-10 CA CA2970315A patent/CA2970315C/en active Active
- 2015-12-10 EP EP15819965.3A patent/EP3230316B1/en active Active
- 2015-12-10 HR HRP20220066TT patent/HRP20220066T1/hr unknown
- 2015-12-10 DK DK15819965.3T patent/DK3230316T3/da active
- 2015-12-10 RS RS20220058A patent/RS62827B1/sr unknown
- 2015-12-10 CN CN201580066980.8A patent/CN106999511A/zh active Pending
- 2015-12-10 SI SI201531805T patent/SI3230316T1/sl unknown
- 2015-12-10 EP EP21207057.7A patent/EP3985023A1/en active Pending
- 2015-12-10 CN CN202110181096.6A patent/CN112826934A/zh active Pending
- 2015-12-10 JP JP2017530277A patent/JP7320919B2/ja active Active
- 2015-12-10 PT PT158199653T patent/PT3230316T/pt unknown
-
2019
- 2019-06-26 US US16/453,242 patent/US20190381008A1/en active Pending
-
2020
- 2020-10-15 JP JP2020173951A patent/JP2021004262A/ja active Pending
-
2021
- 2021-10-08 AU AU2021107575A patent/AU2021107575A4/en not_active Expired
- 2021-10-08 AU AU2021245214A patent/AU2021245214A1/en active Pending
-
2022
- 2022-09-26 JP JP2022152791A patent/JP2022183183A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002062386A2 (en) * | 2001-02-06 | 2002-08-15 | Qlt Inc. | Photodynamic therapy of occult choroidal neovascularization linked to age-related macular degeneration |
Non-Patent Citations (1)
Title |
---|
GUI-SHUANG YING: "BASELINE PREDICTORS FOR ONE-YEAR VISUAL OUTCOMES WITH RANIBIZUMAB OR BEVACIZUMAB FOR 以下備考", OPHTHALMOLOGY, vol. VOL:120, NR:1,, JPN5017010274, 2013, US, pages 122 - 129, ISSN: 0004142587 * |
Also Published As
Publication number | Publication date |
---|---|
WO2016094673A1 (en) | 2016-06-16 |
PL3230316T3 (pl) | 2022-05-02 |
AU2015360496B2 (en) | 2021-09-30 |
CN112826934A (zh) | 2021-05-25 |
DK3230316T3 (da) | 2022-03-28 |
RS62827B1 (sr) | 2022-02-28 |
EP3230316A1 (en) | 2017-10-18 |
AU2021107575A4 (en) | 2022-01-06 |
ES2907148T3 (es) | 2022-04-22 |
CN106999511A (zh) | 2017-08-01 |
LT3230316T (lt) | 2022-02-10 |
CA2970315C (en) | 2023-08-22 |
AU2021245214A1 (en) | 2021-11-04 |
EP3230316B1 (en) | 2022-01-05 |
AU2015360496A1 (en) | 2017-05-25 |
JP2022183183A (ja) | 2022-12-08 |
HUE057653T2 (hu) | 2022-05-28 |
US20170326106A1 (en) | 2017-11-16 |
US20190381008A1 (en) | 2019-12-19 |
EP3985023A1 (en) | 2022-04-20 |
SI3230316T1 (sl) | 2022-05-31 |
JP2021004262A (ja) | 2021-01-14 |
HRP20220066T1 (hr) | 2022-04-15 |
CN114306575A (zh) | 2022-04-12 |
CA2970315A1 (en) | 2016-06-16 |
PT3230316T (pt) | 2022-02-24 |
JP7320919B2 (ja) | 2023-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021107575A4 (en) | Treatment of age related macular degeneration with a small active choroidal neovascularization lesion | |
Schmidt-Erfurth et al. | Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six–week results of the VIEW studies | |
Cho et al. | Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy | |
Lazic et al. | Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration | |
Anecortave Acetate Clinical Study Group | Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes | |
JP2019167366A (ja) | 血管新生眼疾患を処置するためのvegfアンタゴニストの使用 | |
Kourlas et al. | Ranibizumab for the treatment of neovascular age-related macular degeneration: a review | |
Brown et al. | Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration–primary end point | |
Sato et al. | Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy | |
Donnenfeld et al. | Safety of IBI-10090 for inflammation associated with cataract surgery: phase 3 multicenter study | |
Jain et al. | Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirty-six-month results | |
US20040127472A1 (en) | Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration | |
Krebs et al. | Efficacy of intravitreal bevacizumab (Avastin®) therapy for early and advanced neovascular age‐related macular degeneration | |
Shantha et al. | Choroidal neovascularization associated with birdshot chorioretinopathy | |
WO2016090590A1 (en) | Treatment of age related macular degeneration with a small active choroidalneovascularizationlesion | |
Kodjikian et al. | Efficacy and safety of Aflibercept for the treatment of inflammatory choroidal neovascularization: The ALINEA study | |
Todd et al. | Diagnosis and management of Serpiginous choroiditis | |
KR20160013026A (ko) | 폴립양 맥락막 혈관병증의 치료 | |
Shah et al. | Clinical Trials in Age-related Macular Degeneration-IV | |
Alezzanarini et al. | Update in the Management of Exudative Age | |
Sivaprasad | S Jyothi, HR Chowdhury, V Chong and | |
Kamiya et al. | 2 Refractive Surgery | |
Ionides et al. | Vitreous, Choroid, and Retina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181207 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191105 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200129 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200615 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201015 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20201015 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20201028 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20201102 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20201228 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20210112 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20211018 |
|
C27C | Written answer of applicant after an oral proceeding |
Free format text: JAPANESE INTERMEDIATE CODE: C2721 Effective date: 20220104 |
|
C27B | Notice of submission of publications, etc. [third party observations] |
Free format text: JAPANESE INTERMEDIATE CODE: C2714 Effective date: 20220221 |
|
C092 | Termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C092 Effective date: 20220308 |
|
C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20220404 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20220418 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220704 |
|
C27B | Notice of submission of publications, etc. [third party observations] |
Free format text: JAPANESE INTERMEDIATE CODE: C2714 Effective date: 20221017 |
|
C27B | Notice of submission of publications, etc. [third party observations] |
Free format text: JAPANESE INTERMEDIATE CODE: C2714 Effective date: 20221212 |
|
C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20230220 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230522 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230725 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7320919 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |